Fertility sparing management of endometrial adenocarcinoma and atypical hyperplasia: a literature review

被引:5
|
作者
Koskas, Martin [1 ]
Yazbeck, Chadi [1 ]
Walker, Francine [2 ]
Delorme, Pierre [1 ]
Azria, Elie [1 ]
Luton, Dominique [1 ]
Madelenat, Patrick
机构
[1] Hop Bichat Claude Bernard, Serv Gynecol Obstet & Anatomopathol, F-75877 Paris 18, France
[2] Hop Bichat Claude Bernard, Serv Anatomopathol, F-75018 Paris, France
关键词
conservative management; fertility sparing; adenocarcinoma; atypical hyperplasia; endometrium; YOUNG-WOMEN; CONSERVATIVE TREATMENT; MEDROXYPROGESTERONE ACETATE; PRESERVING TREATMENT; SUCCESSFUL PREGNANCY; PREMENOPAUSAL WOMEN; HORMONE ANALOGS; CARCINOMA; CANCER; PROGESTIN;
D O I
10.1684/bdc.2011.1516
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In endometrial carcinoma (EC) and atypical hyperplasia (AH) diagnosed in childbearing years, the principle of uterine sparing consists in prescription of antigonadotropic treatment to obtain the remission of the endometrial lesion and allow pregnancy, always with a close follow-up looking for progression or persistence of the tumour. Studies evaluating this strategy have suggested the safety of such an approach, but numerous questions remain unanswered, like those concerning the type and the duration of treatment, and the systematic use of Assisted Reproductive Technologies... We performed a critical literature review in order to analyse patients and tumoral characteristics, treatment management and the results of fertility sparing strategy. This review shows that fertility sparing management of AH and intramucous EC permits to obtain pregnancy in one third of candidates. Few disease-related deaths have been reported after this management. One-third of patients experienced progression lesion beyond the endometrium, but generally limited to the myometrium. Progestins have been widely evaluated in this indication and provide an overall remission rate of 80% with a recurrence risk of 25%. triangle
引用
收藏
页码:51 / 60
页数:10
相关论文
共 50 条
  • [11] Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol
    Fernandez-Montoli, Maria-Eulalia
    Sabadell, Jordi
    Contreras-Perez, Nayanar-Adela
    ADVANCES IN THERAPY, 2021, 38 (05) : 2717 - 2731
  • [12] Progression of fertility-sparing treatment for atypical endometrial hyperplasia in a woman with lynch syndrome: a case report and review of the literature
    Hsu, Ya-Ting
    Chen, Chi-Hau
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [13] Impact of In Vitro Fertilization treatments on the risk of recurrence in fertility-sparing management of endometrial atypical hyperplasia and grade I adenocarcinoma
    Vaugon, M.
    Peigne, M.
    Larouzee, E.
    Phelippeau, J.
    Gonthier, C.
    Koskas, M.
    HUMAN REPRODUCTION, 2020, 35 : 19 - 20
  • [14] Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy
    Chen, Junyu
    Cao, Dongyan
    Yang, Jiaxin
    Yu, Mei
    Zhou, Huimei
    Cheng, Ninghai
    Wang, Jinhui
    Zhang, Ying
    Peng, Peng
    Shen, Keng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [15] Quality of information and decision regret during fertility sparing management for atypical hyperplasia and endometrial cancer
    Haim, Noemie
    Vandenbroucke, Tineke
    Bourdet, Alice
    Amant, Frederic
    Koskas, Martin
    PSYCHO-ONCOLOGY, 2017, 26 : 70 - 70
  • [16] Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity
    Chen, Junyu
    Cao, Dongyan
    Yang, Jiaxin
    Yu, Mei
    Zhou, Huimei
    Cheng, Ninghai
    Wang, Jinhui
    Zhang, Ying
    Peng, Peng
    Shen, Keng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [17] Molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia
    Martin, Tiermes Marina
    Matas, Isabel
    Munmany, Meritxell
    Celada, Cristina
    Diaz-Feijoo, Berta
    Glickman, Ariel
    Carreras, Nuria
    Fuste, Pere
    Torne, Aureli
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A245 - A246
  • [18] Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments
    Yin, Jie
    Ma, Shuai
    Shan, Ying
    Wang, Yongxue
    Li, Yan
    Jin, Ying
    Pan, Lingya
    CANCER PREVENTION RESEARCH, 2020, 13 (04) : 403 - 409
  • [19] Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer
    Gonthier, Clementine
    Walker, Francine
    Luton, Dominique
    Yazbeck, Chadi
    Madelenat, Patrick
    Koskas, Martin
    GYNECOLOGIC ONCOLOGY, 2014, 133 (01) : 33 - 37
  • [20] A practical guideline on the fertility-sparing treatment of patients with endometrial carcinoma and atypical endometrial hyperplasia
    Catena, Ursula
    Macklon, Kirsten Louise Tryde
    Rodolakis, Alexandros
    Scambia, Giovanni
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2025,